By administering CXCL10 neutralizing antibody (Invitrogen, CA, USA) or an isotypic control (mIgG) preventively to the CCl4-treated mice, we found that CXCL10 neutralizing antibody significantly attenuates CCl4 induced liver fibrosis as indicated by reduced collagen deposition in whole liver lysate (Fig. 7a). This evidence concerns the gene CXCL10 and Hepatic fibrosis.